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Dissociation of Cardiogenic and Postnatal Myocardial Activities of
GATA4
Joseph M. Gallagher,a Hiba Komati,b Emmanuel Roy,c Mona Nemer,b,c and Branko V. Latinkic´a
School of Biosciences, Cardiff University, Museum Avenue, Cardiff, United Kingdoma; Laboratory of Cardiac Development and Differentiation, Department of
Biochemistry, Microbiology, and Immunology, University of Ottawa, Ottawa, Ontario, Canadab; and Graduate Program in Biomedical Sciences, University of Montréal,
Montréal, Québec, Canadac
Transcription factor GATA4 is a critical regulator of the embryonic and postnatal heart, but the mechanisms and cofactors re-
quired for its diverse functions are not fully understood. Here, we show that whereas the N-terminal domain of GATA4 is re-
quired for inducing cardiogenesis and for promoting postnatal cardiomyocyte survival, distinct residues and domains therein
are necessary to mediate these effects. Cardiogenic activity of GATA4 requires a 24-amino-acid (aa) region (aa 129 to 152) which
is needed for transcriptional synergy and physical interaction with BAF60c. The same region is not essential for induction of
endoderm or blood cell markers by GATA4, suggesting that it acts as a cell-type-specific transcriptional activation domain. On
the other hand, a serine residue at position 105, which is a known target for mitogen-activated protein kinase (MAPK) phos-
phorylation, is necessary for GATA4-dependent cardiac myocyte survival and hypertrophy but is entirely dispensable for
GATA4-induced cardiogenesis. We find that S105 is differentially required for transcriptional synergy between GATA4 and se-
rum response factor (SRF) but not other cardiac cofactors such as TBX5 and NKX2.5. The findings provide new insight into
GATA4mechanisms of action and suggest that distinct regulatory pathways regulate activities of GATA4 in embryonic develop-
ment and postnatal hearts.
Vertebrate heart development is a complex, multistage processthat begins with specification during gastrulation and contin-
ues well after birth. Throughout embryonic development, cells
fated to give rise to the heart undergo well-orchestratedmolecular
events that control their proliferation, migration, and differentia-
tion. Virtually all aspects of heart development are regulated by a
set of conserved cardiac transcription factors, which have been
well characterized by a combination of genetic and biochemical
approaches. They include the zinc finger proteins GATA4/
GATA5/GATA6 (GATA4/5/6), the MADS-domain factors MEF2
and serum response factor (SRF), theNKX2.5 homeodomain pro-
tein, the basic helix-loop-helix (bHLH) proteins HAND1 and -2,
and the T-box factors TBX2/TBX5/TBX20 (33, 36). Spatial and
temporal specificity may be achieved through the formation of
multiprotein complexes that contain a subset of these factors
along with other inducible or ubiquitous transcriptional regula-
tors (10, 11, 26, 31). Generation of animal models lacking specific
factors has started to shed light on the in vivo interactions of these
proteins at various stages of cardiogenesis (20, 22, 31). Moreover,
biochemical analyses of disease-causing human mutations are
providing some insight into structural determinants of multipro-
tein complex formation (13).
GATA4, amember of the evolutionarily conserved GATA pro-
teins, has emerged as a critical regulator of cardiogenesis either
directly in cardiac precursors or through its role in the adjacent
endoderm, where it can modulate cardiogenic factors like bone
morphogenetic proteins (BMPs) (32). Mouse embryos lacking
GATA4 die at embryonic day 8.5 (E8.5) to E9 due to abnormal
heart morphogenesis (27) while mice with hypomorphic Gata4
alleles show reduced viability due to a spectrum of congenital
heart diseases (38). Loss of GATA4 specifically in endothelial or
myocardial cells also leads to congenital heart defects (CHD), un-
derscoring the important role for GATA4 in both cell lineages (48,
50). Human genetics have confirmed the essential role of GATA4
in valve and septal formation as evidenced by the finding of
GATA4mutations in association with several forms of CHD (39).
Loss- and gain-of-function studies have also shown that GATA4 is
a potent inducer of cardiogenesis. For example, GATA4 down-
regulation blocks embryonic stem cell cardiogenesis at an early
stage while ectopic GATA4 enhances cardiogenesis therein and
formation of beating cardiomyocytes (15). In Xenopus embryos,
gain of function of GATA4 is sufficient to induce cardiogenesis in
embryonic ectoderm (21).More recently, GATA4 in combination
with cofactors such as BAF60c and TBX5 was shown to be suffi-
cient to induce cardiogenesis in heterologous murine cells (17,
44). BAF60c is a broadly expressed subunit of the SWI/SNF-like
BAF chromatin remodeling complex, with high levels found in the
heart (7, 24, 47). In vitro BAF60c mediates interaction of cardiac
transcription factors GATA4, NKX2.5, and TBX5 with the SWI/
SNF complex ATPase Brg1, resulting in strong transcriptional
synergy (24). The interaction of BAF60c with cardiac transcrip-
tion factors may underlie its essential role in heart development
(24). Despite this recent progress, how GATA4 interacts with
BAF60c and more generally how it induces cardiogenesis are in-
completely understood.
In addition to its role during development, GATA4 is an essen-
tial regulator of the postnatal and adult heart, where it modulates
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growth and survival of the terminally differentiated myocytes (1,
5, 35), and is essential for the heart adaptive response to stress and
ischemic injury (35, 37, 40). In particular, GATA4 appears to be
essential, and its upregulation is sufficient to promote myocyte
survival, in part through transcriptional regulation of the antiapo-
ptotic Bcl-XL and Bcl-2 genes (1, 19). Similarly, GATA4 is an es-
sential nuclear effector of numerous signaling pathways that are
activated by hormones and growth factors that cause myocyte
enlargement and cardiac hypertrophy (5, 37, 46). Whether such
gain-of-function effects necessitate the presence of specific amino
acid residues or protein domains and whether those are identical
to the domains required for the cardiogenic activity of GATA4
remain to be determined. For example, the activity of GATA4 is
upregulated in response to signaling pathways critical for embryo-
genesis and for cardiac hypertrophy, such as the extracellular sig-
nal-regulated kinase (ERK)/mitogen-activated protein kinase
(MAPK) pathway, which phosphorylate GATA4 at S105 (5, 23).
However, the importance of this residue in the various GATA4
functions has not yet been determined.
In this report we have directly tested the potential link between
the mechanisms by which GATA4 exerts its survival, hypertro-
phic, and cardiogenic functions through structure-function anal-
ysis.Wemapped a 24-amino-acid (aa) region essential for cardio-
genesis and for transcriptional synergy and physical interaction
with BAF60c. In addition we determined that phosphorylation of
S105 is required for hypertrophy and survival of cardiac myocytes
but not for cardiogenesis. The results provide insight into the dis-
tinct mechanisms through which multiple roles of GATA4 are
mediated.
MATERIALS AND METHODS
Xenopus embryos and explants.All animalworkwas approved byCardiff
University’s Ethical Review Committee and was undertaken under a li-
cense from the Home Office of the United Kingdom. Xenopus embryos
were obtained and cultured as previously described (43). Explants (stage
8.5) were dissected and cultured in 75% normal amphibian medium
(NAM), supplemented with gentamicin sulfate (50 g/ml; Sigma). Xeno-
pus GATA4 (xGATA4) and GATA1 templates for in vitro transcription
have been described previously (21). All rat GATA4 (rGATA4) constructs
were linearized with Asp718 (Roche). Capped mRNA was synthesized
using amMessageMachine kit (Ambion/ABI), andRNAwas subsequently
purified on Sephadex G50 columns (GE Healthcare). RNA samples were
injected into embryos using an IM-300 Microinjector (Narishige Scien-
tific). RNA (400 pg) was coinjected with a mix of rhodamine-dextran (20
mg/ml) and dextran-biotin (25 mg/ml) lineage tracers (Invitrogen) (21,
43) in 10 nl/embryo at the 1- to 2-cell-stage. For ectopic cardiac tissue
formation assay, 2 nl (80 pg) of RNA was injected in one anterior dorsal
blastomere at the 8- to 16-cell stage. These precursors of the central ner-
vous system are away from the developing heart and were chosen to assay
genuine ectopic cardiac tissue induction. Translation-blocking morpho-
lino oligonucleotides against GATA4 were used as described previously
(16), and their effectiveness was confirmed by phenotypic analysis of sib-
ling embryos.
Reverse transcription-PCR (RT-PCR). Total RNA was isolated from
samples using the acid guanidinium thiocyanate-phenol-chloroform
method (6). Approximately 20 animal caps were used per sample, and
cDNA was synthesized using Moloney murine leukemia virus (MMLV)
reverse transcriptase (RT) and random hexamers (both Invitrogen) ac-
cording to the manufacturer’s instructions. Primer sequences and cycling
conditions were as described previously (41). PCR was performed with
GoTaq enzyme (Promega). Whole-mount in situ hybridization was car-
ried out as described previously (43), using the digoxigenin (Roche)-la-
beled antisense riboprobe for MLC2 (3). Color was developed using BM
purple (Roche).
Immunohistochemistry on blastula stage Xenopus embryos was per-
formed as described previously (43), using ratmonoclonal antihemagglu-
tinin (anti-HA)-horseradish peroxidase (HRP) (1:2,500; Roche) and di-
aminobenzidine (DAB) substrate (Sigma). Images were taken on a Leica
MZ16 stereomicroscope with a DFC300FX Leica camera and were pro-
cessed with Adobe Photoshop software.
Western blotting. Western blotting of Xenopus protein extracts was
performed as described previously (9). Total cell extracts were prepared
from 1 to 2 l of lysis buffer-animal cap or from cultured cells. Ten-
microliter samples were resolved by polyacrylamide gel electrophoresis
and transferred to polyvinylidene difluoride (PVDF) membrane (Milli-
pore) and blotted by standard techniques. Antibodies used were rat
monoclonal anti-HA-HRP (1:2,500; Roche) and, as a loading control,
anti-Erk (1:2,500; Santa Cruz). Secondary antibody was goat anti-rabbit
antibody–HRP (1:5,000; Chemicon). Detection was achieved using a
chemiluminescent detection kit (Pierce). Western blotting on nuclear ex-
tracts from cardiac myocytes or other cell lines overexpressing various
GATA4 proteins was performed as previously described (5). HA antibody
at a 1/500 dilution andBcl-XS/L (S-18) antibody at 1/1,000were both from
Santa Cruz. Visualizationwas performed using an anti-rabbit horseradish
peroxidase-conjugated antibody (Sigma).
Recombinant DNA. For gain-of-function studies in Xenopus, rat
GATA4 sequences together with an N-terminal HA tag were generated by
high-fidelity PCR and were cloned in pCS2 vector via BamHI/EcoRI sites.
Primer sequences are available upon request. Adenoviral constructs ex-
pressing HA-tagged GATA4 (GATA4 wild type [WT], GATA4 with the
S105Amutation [GATA4-S105A], and GATA4 consisting of residues 201
to 440 [GATA4(201–440)]) in recombinant replication-deficient type 5
adenovirus (Ad5) were generated using an AdEasy XL adenoviral vector
system (Stratagene). cDNAs of the corresponding rat GATA4 constructs
were subcloned into Ad5 shuttle vector pshuttle using HindIII and
EcoRV, and the adenoviruses were generated through recombination
with the pAdEasy-1 as described previously (8). Transformant bacteria
were selected for kanamycin resistance, and recombination was identified
via restriction enzymedigestion. Recombinantswere then amplified using
FIG 1 Rat GATA4 induces cardiac tissue in Xenopus animal caps indepen-
dently of endogenous xGATA4. (A) Animal cap explants injected with 500 pg
of indicated mRNAs have been analyzed for expression of cardiac (MLC2 and
alpha-myosin heavy chain [MHC]), endothelial (MSR), blood (globin), and
liver (For1) markers at stage 34. Hex marks both liver and endothelia (34).
rGATA4 and xGATA4 induce all markers tested, whereas xGATA1 induces
only blood and endothelia. (B) rGATA4 induces endogenous GATA4 expres-
sion at stage 10, approximately 3 h after activation of zygotic gene expression.
(C) Morpholino oligonucleotides against xGATA4 (4MO) do not prevent in-
duction of cardiac markers by rGATA4. ODC, ornithine decarboxylase, load-
ing control; AC, control animal caps; embryo, cDNA from sibling control
embryos;RT, no reverse transcriptase control for the embryo sample.
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the recombination-deficient Escherichia coli strain Epicurian Coli XL10-
Gold. Purified recombinant adenoviral plasmid DNA was digested with
PacI to expose the terminal repeats and was later transfected to AD-293
cells in which deleted viral assembly genes are complemented in vivo. The
viruses were produced in bulk, and titers were determined as reported
previously (8).
Electrophoreticmobility shift assays.DNA binding of GATA4 vari-
ants was assessed as described previously (46). Nuclear extracts were
obtained from cultured 293T cells overexpressing GATA4 constructs,
and the 120 atrial natriuretic factor (ANF) GATA site was used as a
probe.
Luciferase assays. Xenopus embryos were injected with indicated
RNAs together with 30 pg each of 2XGATALuc, a luciferase reporter
driven by two GATA elements in front of BNP50bp, (14) and TK-RL
(Promega). Dual luciferase assays (Promega) were carried out on extracts
from approximately 20 animal caps per sample that were incubated for
3 h after excision at stage 9.
NIH 3T3 cells were cultured and transfected, and luciferase assays
using ANF reporter plasmids and GATA4, NKX2.5, Tbx5, MEF2C, and
SRF expression vectors were carried out as previously described (8, 10).
All experiments were repeated at least three times in duplicate.
Cardiomyocyte cultures and infections. Ex vivo experiments were
done on primary cultures of rat neonatal cardiomyocytes as previously
described (5). Cardiomyocytes were plated and kept overnight in Dulbec-
co’smodified Eaglemedium containing 10% fetal bovine serum. The next
day, cells were extensively washed, and the medium was replaced with
serum-free, hormone-free medium. Cardiomyocytes were infected at a
multiplicity of infection (MOI) of 5 with either adeno-LacZ, adeno-
FIG 2 The rGATA4 domain of aa 129 to 153 is required for cardiogenesis. (A) Schematic representation of GATA4 protein showing the position of mutations/
deletions in green.NLS, nuclear localization signal. (B andD)Explants injectedwith indicated rGATA4 variantswere tested for expression of alpha-myosin heavy
chain (MHC) at stage 34 (top) and by Western blotting for the levels of rGATA4 protein at stage 10 (below). Panel B (bottom) shows nuclear localization as
determined by whole-mount immunohistochemistry with anti-HA–HRP at stages 6 to 8. (C) Noncardiogenic rGATA4(201–440) protein is stable throughout
the cultivation period. Samples collected at indicated stages were analyzed for rGATA4 and ERK byWestern blotting. rGATA4 protein was detected by anti-HA
(B and C) or anti-human GATA4 antibodies (D). (E) Stage 34 embryos injected with indicated mRNAs in anterior ectodermal precursor blastomeres were
analyzed for MLC2 expression, highlighting the heart (h) and ectopic MLC2 expression (arrow). More than 50 embryos were analyzed for each construct, with
15 to 20% showing ectopic expression in the case of cardiogenic constructs.
Gallagher et al.
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GATA4-WT, adeno-GATA4-S105A, or adeno-GATA4(201–440) as de-
scribed previously (1, 4). Treatment with doxorubicin (Dox) was as de-
scribed previously (1). Immunofluorescence on cardiomyocytes was
performed as previously described (8), using a rabbit polyclonal HA an-
tibody (dilution, 1/500) from Santa Cruz and phalloidin-Alexa Fluor 488
(dilution, 1/400). Apoptosis was detected by a terminal deoxynucleotidyl-
transferase-mediated dUTP nick end labeling (TUNEL) assay as recom-
mended in the Apoptag kit (Chemicon). An average of 10 random fields
with 100 nuclei per field were analyzed.
Coimmunoprecipitation. Coimmunoprecipitation of HA-GATA4
constructs and endogenous BAF60cwas carried out using nuclear extracts
of 293T cells overexpressing the relevant proteins. Nuclear extracts were
prepared as previously described (28). Coimmunoprecipitation reactions
were carried out on 60g of nuclear extracts using 2g of rabbit BAF60c
antibody. Proteins were separated by 10% SDS-PAGE, transferred to
PVDF membranes, and subjected to immunoblotting using either
anti-HA antibody to reveal tagged GATA4 proteins or anti-BAF60c anti-
body to reveal endogenous BAf60c protein.
Statistical analysis.Data are means the standard error of the mean
(SEM), with a P value of 0.05 by a Student’s t test being considered
statistically significant.
RESULTS
Mammalian GATA4 induces cardiac differentiation in pluripo-
tent Xenopus embryo explants. In addition to promoting cardi-
omyocyte growth and survival, GATA4 can induce cardiogenesis,
an activity that reflects its role in early heart development. To test
the requirement of the N-terminal region for GATA4-induced
cardiogenesis, we used a Xenopus animal pole explant assay (ani-
mal caps). This assay was established for the Xenopus GATA4,
which, when ectopically expressed in animal caps, respecifies
them from epidermal to cardiomyocyte fate (21). As expected
from a high degree of sequence conservation (61% overall amino
acid identity and 71% similarity), the rat GATA4 behaves indis-
tinguishably from the Xenopus GATA4 in animal cap assays as it
induces cardiomyocyte (as well as blood, endothelium, and liver)
markers (Fig. 1A). In contrast, the hematopoietic factor GATA1
induces only blood and endothelium markers, attesting to the
specificity of the assay (Fig. 1A). An early target of the exogenous
GATA4 in animal caps is the endogenous gata4 gene (Fig. 1B). As
it is possible that rGATA4 induces cardiac differentiationmarkers
through early activation of the endogenousGATA4, the assaymay
not accurately reflect the true cardiogenic activity of the exoge-
nous rGATA4 protein.We addressed the question of requirement
of xGATA4 for cardiogenesis triggered by rat GATA4 by using
previously described antisense morpholino oligonucleotides
against xGATA4 (16). As shown in Fig. 1C, our results demon-
strate that the endogenous GATA4 protein is not required for
cardiogenesis induced by the rat GATA4, arguing that the animal
cap assay reflects intrinsic cardiogenic activity of the rGATA4 pro-
tein.
The N-terminal 129 amino acids of GATA4 are dispensable
for cardiogenic activity.Wenext tested the cardiogenic activity of
GATA4mutants lacking part of or the entire N-terminal domain,
schematically represented in Fig. 2A. As shown in Fig. 2B, the
GATA4(201–440) mutant, which lacks the entire N-terminal ac-
tivation domain, was defective in cardiogenic activity. However,
and as previously reported (4), it localized to the nucleus (Fig. 2B)
and was stable at several time points during cultivation of animal
cap explants (Fig. 2C), indicating that lack of cardiogenic activity
is not caused bymislocalization, reduced protein stability, or a loss
of cells expressing it. To further delineate the cardiogenic do-
main(s), smaller N-terminal deletions were tested. Removal of the
first 96 or 129 amino acids hadno effect on the cardiogenic activity
of GATA4 but further deletion at aa 152 or 181 abrogated cardio-
genic activity (Fig. 2D).
The same rGATA4mutants were also tested in an independent
in vivo assay for their capacity to induce ectopic cardiac tissue in
Xenopus embryoswhen overexpressed in anterior ectodermal pre-
FIG 3 Noncardiogenic mutants GATA4(153–440) and GATA4(201–440) re-
tain transcriptional activity. (A) Transcriptional activity of various GATA4
(G4) N-terminal deletion mutants. Cotransfections in NIH 3T3 cells were
carried out on 1.5 g of the (GATA)3-Luc reporter, and 25, 50, and 100 ng of
each GATA4 construct. (B) Western blot showing protein levels of expression
of GATA4 constructs (top) and gel shift assay showing the ability of GATA4
mutants to bind DNA (bottom). The probe used is the GATA element at
position120 on theNppa (ANF gene) promoter. (C)Removal of the first 153
or 201 amino acids from rGATA4 attenuates, but does not abolish, the ability
to activate a GATA site-driven reporter. Embryos were injected with a firefly
luciferase reporter under the control of two GATA sites, Renilla luciferase
plasmid driven by the thymidine kinase (TK) promoter and indicatedmRNAs.
Control, DNA alone (no RNA). Animal caps were collected 3 h after excision.
GATA activity is firefly luciferase activity normalized for Renilla luciferase
activity, expressed as fold activation over the control sample. A representative
of three repeated experiments is shown. (D) Noncardiogenic mutants consist-
ing of GATA4 aa 153 to 440 and 201 to 440 can induce the endogenous gata4
gene both early (stage 10) and late (stage 34), as revealed by RT-PCR analysis.
(E and F) rGATA4mutants consisting of GATA4 aa 153 to 440 and 201 to 440
cannot induce cardiomyocyte-specific markers MLC2, MHC, and cardiac
troponin I (cTnI) but retain the capacity to induce globin, a marker of blood
(albeit at a lower level) as well as endodermal markers Sox17 at stage 10 and
endodermin at stage 34. RT-PCR analysis was performed on stage 34 animal
caps. AC, control animal caps.
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cursors. We found that the cardiogenic activity of rGATA4 mu-
tants in animal cap explants perfectly correlated with their ability
to induce ectopic cardiac tissue in vivo (Fig. 2E), suggesting that
context-dependent modulation of cardiogenic activity of GATA4
is unlikely.
Noncardiogenic GATA4 mutants might be inactive simply
because their transactivation function was severely compro-
mised by deletion of one or more N-terminal activation do-
mains (30). When assayed by using a GATA site-dependent
luciferase reporter, transcriptional activity of noncardiogenic
mutants GATA4(153–440) and GATA4(201–440) was shown
to be attenuated (Fig. 3A and C) although their DNA binding
was not affected (Fig. 3B). Remarkably, the noncardiogenic
mutants were able to induce the endogenous gata4 gene (Fig.
3D) as well as the markers of blood and endoderm (Fig. 3E and
F). This result suggests that the determinants for specification
of cardiomyocyte, blood, and endodermal cell fates by GATA4
are separable. In addition, the reporter assay suggests that, in
contrast to cardiomyocyte induction, the induction of blood
and endoderm does not require the intact transcriptional ac-
tivity of GATA4.
The lack of cardiogenic activity of the GATA4(153–440) and
GATA4(201- 440) mutants was confirmed by examining the ex-
pression of additional cardiomyocyte-specific markers such as
MLC2 and troponin I (Fig. 3E). Together, the results suggest that
amino acids 129 to 153 of GATA4 are specifically required for its
cardiogenic activity. Since neither altered expression, nuclear ac-
cumulation, nor DNA binding could account for loss of cardio-
genic activity when aa 129 to 153 were deleted, we reasoned that
disruption of cofactor(s) interaction may underlie loss of cardio-
genic activity.
S105 phosphorylation is not required for cardiogenesis in-
duced by GATA4. As stated earlier, S105 is a major MAPK phos-
phorylation site. Although it resides outside the cardiogenic do-
main defined above, we tested its requirement for cardiogenesis,
given the important role of MAPK in heart development. Our
results demonstrate that a nonphosphorylatable S105A mutation
is as efficient at inducing cardiogenesis as the native GATA4 pro-
tein as evidenced by similar levels of cardiac marker induction
(Fig. 4). Interestingly, the phosphomimetic mutation S105E con-
sistently increased the level of GATA4-induced cardiac markers
(Fig. 4C andD). Thus, S105 phosphorylationmay not be required
for cardiogenesis but may instead have a positive modulatory ef-
fect.
N-terminal cardiogenic region of GATA4 (aa 129 to 152) is
required for interaction with BAF60c.When tested for its ability
to cooperate with NKX2.5, TBX5, and MEF2A in transcriptional
activation, a GATA4mutant lacking the first 152 aa was unable to
support significant synergy with any of them (Fig. 5A and B). This
result could not be attributable to impaired physical interactions
FIG 4 S105 phosphorylation is not required for cardiogenesis by rGATA4. (A) Transcriptional activity of GATA4 S105A and S105E mutants. Cotransfections
in NIH 3T3 cells were carried out on 1.5 g of the (GATA)3-Luc reporter, and 25, 50, and 100 ng of each of the GATA4 constructs. (B) Western blot showing
nuclear GATA4 protein levels in transfected cells (top) and gel shift assay showing the ability of GATA4 mutants to bind DNA (bottom). The probe used is the
GATA element at position 120 on the Nppa promoter. (C) S105A and S105E rGATA4 variants induce at state 34 markers of cardiomyocyte differentiation
MLC2 andMHC. S105E induces a greater amount of cardiac markers than theWT or S105A rGATA (top). AWestern blot shows levels of rGATA4 variants at
stage 10, detected with anti-HA antibody (middle). Nuclear localization as determined by whole-mount immunohistochemistry with anti-HA–HRP is shown at
stages 6 to 8 (bottom). (D) Indicated rGATA4 variants induce ectopic MLC2 expression in stage 34 embryos. More than 50 embryos were examined for each
construct, and 15 to 20% showed ectopic expression. AC, control animal caps.
Gallagher et al.
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with the mutant GATA4 proteins lacking aa 129 to 153 as earlier
studies established that in all three cases the GATA4-interacting
domain resides in the second zinc finger (2, 10, 28). We then
assessed the ability of all GATA4 proteins to interact with BAF60c,
the cardiac-enriched subunit of BAF chromatin remodeling com-
plexes, that was shown to be essential for the ectopic cardiogenic
activity of GATA4 (44). The GATA4(153–440) mutant was un-
able to synergize with BAF60c, providing the potential underlying
cause for its lack of cardiogenic activity (Fig. 5C). Because BAF60c
was shown to potentiate cardiogenic function by physically inter-
actingwithGATA4 and enhancing its transcriptional activation of
cardiac genes, we checked the ability of GATA4 N-terminal dele-
tions to interact with BAF60c. Our results show that both
GATA4-WT and the GATA4(129–440) mutant strongly interact
with BAF60c protein. In contrast, the GATA4(153–440) mutant
shows greatly reduced protein-protein interaction, suggesting a
mechanism of action of the region of aa 129 to 152 in GATA4
cardiogenic function (Fig. 5D).
S105 is required for functional synergy with SRF and for hy-
pertrophic and cell survival-promoting activities.Previously,we
showed that ectopic expression of GATA4 in postnatal cardiomy-
ocytes induced cytoskeletal reorganization and hypertrophy. This
effect mimicked the response of cardiomyocytes to hypertrophic
stimuli which require GATA4 presence and lead to MAPK-medi-
ated S105 phosphorylation (5). To determine if the N-terminal
activation domain of GATA4 and phosphorylation of S105 within
it are required for this effect, we generated adenovirus vectors
expressing HA-tagged wild-type GATA4, as well as HA-tagged
mutants that delete the entire N terminus (aa 201 to 440) or har-
bor a point mutation at S105 (S105A). Infecting the neonatal car-
diomyocytes with these constructs led to comparable exogenous
nuclear protein levels, as assessed byWestern blotting (Fig. 6B). As
expected, overexpression of GATA4-WT inducedmyofibrillar re-
organization andmyocyte hypertrophy (Fig. 6A andC).Myocytes
expressing GATA4-S105A and GATA4(201 to 440) showed re-
ducedmyofibrillar and growth response compared toGATA4WT
(Fig. 6A and C).
Because GATA4 can rescue cardiomyocytes from doxorubicin
(Dox)-induced apoptosis (1), we tested the effect of the different
GATA4mutants on cell survival using a TUNEL assay to measure
myocyte apoptosis. Overexpression of GATA4 significantly atten-
uatedDox-inducedmyocyte apoptosis, as evidenced by the reduc-
tion in the percentage of apoptotic nuclei (Fig. 6D). In contrast,
cells infected with the GATA4-S105A and GATA4(201–440) vec-
tors showed significantly decreased survival in the absence of Dox
(P  0.05) compared to cells infected with the WT GATA4 ade-
novirus or with the control LacZ adenovirus. Furthermore, nei-
ther of the mutant GATA4 vectors could rescue Dox-induced
apoptosis, as evidenced by the significant increase in the per-
centage of TUNEL-positive nuclei (Fig. 6D). To elucidate the
mechanism(s) underlying loss of prosurvival activity, we tested
the transcriptional activity of the different constructs on the
antiapoptotic gene Bcl-XL. As shown in Fig. 6E (right panel)
GATA4 WT, but not the mutants, activates Bcl-XL promoter.
Moreover, Western blot analysis showed upregulated Bcl-XL
protein levels in myocytes expressing GATA4 WT but not in
cells expressing GATA4-S105A and GATA4(201–440) mutants
(Fig. 6E, left panel), leading to a higher ratio of the short pro-
FIG 5 GATA4 regions required for functional cooperativity with cardiac cofactors. (A) Cotransfections in NIH 3T3 cells using 1.5g of the Nppa promoter, 15
ng of each of the GATA4 constructs, and 50 ng each of NKX2.5, TBX5, and MEF2A. The data are the mean SEM of two to three experiments carried out in
duplicate. (B) Histograms showing the fold synergy for each GATA4 mutant. Synergy was calculated from the data in panel A. (C) Cotransfections in NIH 3T3
using 1.5 g of the Nppa promoter, 15 ng of each of the GATA4 constructs, and 250 ng of BAF60c. The data are the mean SEM of three experiments carried
out in duplicate. (D) Immunoprecipitation (IP) of endogenous BAF60c with rabbit anti-BAF60c (kind gift from Puri) followed by detection of transfected
HA-tagged GATA4 mutants. IB, immunoblotting.
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apoptotic Bcl-XS form over the antiapoptotic Bcl-XL form.
Thus, GATA4 growth and survival effects require the N-termi-
nal transcriptional activation domain (TAD) and the presence
of S105 phospho-residue therein.
To better understand the differential effect of S105 on car-
diogenesis versus growth and survival, we tested the effect of
mutating it to a nonphosphorylatable alanine residue or re-
placing it by the phosphomimetic mutation S105E on func-
tional interaction with GATA4 cofactors linked to cardiogen-
esis (TBX5, MEF2, and NKX2.5) or to hypertrophy (SRF).
Interestingly, the S105A mutant specifically affected the syn-
ergy of GATA4 with SRF but not with NKX2.5, TBX5, or MEF2
(Fig. 7A and B). Even though S105 phosphorylation was not
required for synergy of GATA4 with TBX5 and NKX2.5, the
phosphomimetic mutation (S105E) showed enhanced synergy,
a result consistent with its enhanced ability to induce cardio-
genesis (Fig. 4).
DISCUSSION
In this report we have provided evidence thatGATA4 induction of
cardiogenesis, on one hand, and postnatal cardiomyocyte hyper-
trophy and cell survival, on the other, may involve distinct mech-
anisms of action.
Aminoacids129 to152ofGATA4are required for cardiogen-
esis and for interaction with BAF60c. Functional domains of the
GATA family proteins have been studied extensively in vitro, but
relatively little is known about their roles in vivo. Of note, differ-
ences between in vitro and in vivo results were reported for
GATA1: while the N terminus contains a transactivation domain
that is essential in heterologous cells, the deletion of this region of
the protein had no major effect on its ability to rescue GATA1-
deficient mice and to promote hematopoiesis in embryonic stem
(ES) cells (42, 49). Similarly, we found no evidence of an essential
role of the in vitro defined transactivation domain I (aa 1 to 74) of
FIG 6 GATA4 N-terminal domain is essential for myofibrillar reorganization and myocyte survival. (A) Immunofluorescence in cardiomyocyte infected with
the indicated adenoviral constructs. The sarcomeric alpha-actinin was labeled green, and the exogenous GATA4 proteins detected with the anti-HA antibody
were labeled in red. Notice the increase in size of myocytes expressing the WT GATA4 (G4) but not the GATA4(201–440) mutant with an N-terminal deletion
or the S105A GATA4mutant. (B) Western blot confirming similar nuclear overexpression of indicated HA-tagged GATA4 proteins in cardiomyocytes infected
with the corresponding adenoviral vectors. (C) Relative cell surface area wasmeasured across 10 fields (magnification,40) in three separate experiments. *, P
0.05 versus LacZ, GATA4-S105A, andGATA4(201–440). (D)Quantification of TUNEL assays in cardiomyocytes infected with the indicated adenoviruses in the
presence or absence of 300 nM Dox. Notice the apoptotic effect of both GATA4-S105A and GATA4(201–440) mutants. *, P 0.05 versus LacZ; **, P 0.01
versus LacZ; #, P  0.05 versus LacZDox. (E) The left panel shows a Western blot of Bcl-X proteins in nuclear extracts of cardiomyocytes expressing the
indicated constructs. At right, 1.5 g of Bcl-X–luciferase reporter was cotransfected with 25 and 50 ng of each GATA4 construct. The data are the mean SEM
of two to three experiments carried out in duplicate.
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GATA4 (30) in cardiogenesis. In contrast, we have identified a
24-aa region located between aa 129 to 152 required for GATA4-
dependent induction of cardiogenesis, which lies within activa-
tion domain II previously mapped to aa 130 to 177 (25). This
finding suggests a physiological role for activation domain II. The
activation domain II was reportedly required for transcriptional
synergy between GATA4 and other cardiogenic regulators al-
though it is not involved in physical interactions with any of them
(2, 10, 28). Our study uncovers a novel function of the region of aa
129 to 152 in cardiogenesis and suggests that functional and phys-
ical interaction with BAF60c may be the molecular basis for ac-
tion. BAF60c, a component of a multiprotein chromatin remod-
eler, SWI/SNF, was shown to interact with GATA4 and to
stimulate its transcriptional activity (24). In vivo, BAF60c syner-
gizes with GATA4 and GATA5 in inducing ectopic cardiac tissue
(25, 44). GATA4 interacts with the ATPase Brg1, the motor of the
core SWI/SNF complex, but this interaction is enhanced by
BAF60c, providing a possiblemechanism for activation ofGATA4
target genes. Brg1 was shown to interact with the Zn fingers of
GATA factors (18), and in this study we show that BAF60c inter-
action with GATA4 requires the N-terminal region of aa 129 to
152. Together, these findings suggest that GATA4 might interact,
perhaps simultaneously, with two components of the SWI/SNF
complex via different domains. In a recent study on the mecha-
nisms of interaction between BAF60c with themyogenic determi-
nant MyoD, Forcales et al. have suggested a two-step model: first,
BAF60cmediates interaction ofMyoDwith its target promoters in
chromatin, and then, upon signal-induced phosphorylation by
p38, BAF60c recruits the ATPase-containing SWI/SNF com-
plex, resulting in target gene activation and muscle differenti-
ation (12). Whether an analogous dynamic and similarly reg-
ulated model for interaction of GATA4 with BAF60c and SWI/
SNF complex takes place during cardiac specification will be
interesting to investigate.
Cardiac specificity of the GATA4 region of aa 129 to 152 is also
suggested by our results showing that noncardiogenic mutants
GATA4(153–440) and GATA4(201–440) retain the capacity to
induce endoderm and blood markers. Our data also indicate that
noncardiogenic forms of GATA4 perform these activities, despite
their greatly reduced capability to interact with BAF60c. There-
fore, these results further support the essential role of GATA4-
BAF60c interaction in cardiogenesis and suggest that lineage-spe-
cific activities of GATA4may be promoted by distinct parts of the
protein, utilizing different mechanisms and cofactors.
S105 phosphorylation mediates synergy with SRF and myo-
cyte survival.Our studyhas shown that S105Amutation abolishes
GATA4 antiapoptotic activity and significantly reduces its hyper-
trophic effect, but it has no detectable impact on GATA4 cardio-
genic activity either in explants or in vivo. These results suggest
that cardiac hypertrophy is not simply a result of reactivation of
the embryonic program in adult myocytes and instead imply that
the mechanisms underlying these two GATA4-regulated pro-
grams are distinct. These findings are consistent with a recent
report showing that mice with a Gata4 knock-in S105A mutation
have a compromised stress response but show no detectable em-
bryonic defects (45). Furthermore, our results based on gain-of-
function experiments in isolated cardiomyocytes indicate that the
impaired cardiac response is likely due to defective cardiomyocyte
homeostasis. Although they observed increased fibrosis and car-
diac dilation—two processes associated with cardiomyocyte
loss—van Berlo et al. (45) did not note changes in apoptosis in
GATA4-S105 relative to wild-type mice after 2 weeks of pressure
overload; given our findings of the importance of S105 for
GATA4-dependent myocyte survival, it is possible that the time
point chosen for the analysis did not allow detection of increased
apoptosis which may have happened at an earlier stage in these
mice before overt cardiac remodeling. Interestingly, intact S105 is
specifically required for transcriptional synergy between GATA4
and SRF. Both GATA4 and SRF (35) have been shown to be reg-
ulators of cardiac hypertrophy andmyocyte survival. Moreover, a
ternary complex involvingGATA4-SRFbinding to target promot-
erswas shown tomediate transcriptional upregulation in response
to hypertrophic stimulation (29). Our findings suggest that S105
phosphorylation is essential for GATA4-SRF cooperativity and
point to a potential role for SRF-GATA4 synergy in promoting
cardiomyocyte cell survival.
Lastly, although our results indicate that S105 phosphorylation
is not essential for induction of cardiac differentiation by GATA4,
they suggest that this modification may enhance cardiogenic ac-
tivity of GATA4. This role of S105 modification in cardiogenesis
may be the result of increased GATA4 transcriptional activity,
which may be mediated by functional interaction with NKX2.5
FIG 7 GATA4-S105 is required for functional cooperativity with SRF. (A) Cotransfections in NIH 3T3 using 1.5 g of the Nppa promoter, 15 ng of each of the
GATA4 constructs, and 50 ng each of NKX2.5, TBX5, MEF2A, and SRF. The data are the mean  SEM of three experiments carried out in duplicate. (B)
Histograms showing the fold synergy for each GATA4 mutant. Synergy was calculated from the data in panel A.
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and/or TBX5 as the S105E mutation enhances synergy between
these factors, whereas the S105A mutation has no effect. Taken
together with the results from hypertrophy, cardiomyocyte sur-
vival, and biochemical assays (summarized in Table 1), we pro-
pose that regulation of GATA4 activities via phosphorylation of
S105 does not operate as a simple on/off switch between activities.
Instead, there appears to be a hierarchy of effects, where S105
phosphorylation is essential for promoting cell survival and is im-
portant for mediating hypertrophy but plays only a nonessential
modulatory role in cardiogenesis.
In addition to their versatility in regulating multiple aspects of
heart development and homeostasis, cardiac transcription factors
are also important in noncardiac cell types, a property that has
raised a question about the mechanisms through which they
achieve cellular specificity. Our study, focusing on GATA4, sug-
gests that specific domains and posttranslational modifications
may be differentially deployed to achieve distinct cellular outputs.
This would be consistent with human genetics since individuals
harboring GATA4 point mutations linked to congenital heart dis-
ease do not generally show other organ defects. How different
contexts determine differential utilization of GATA4 domains is
not entirely clear and will undoubtedly be the focus of future
research.
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